ORAMED PHARMACEUTICALS INC. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
ORAMED PHARMACEUTICALS INC. (ORMP) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $108.00 thousand for the 101-month period ending 2010-08-31, per its 10-Q filed 2012-07-12.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2014-04-10
- 2010-08-31: Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 101 month $108.00K.
- 2007-08-31: Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 65 month $108.00K.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 65 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 101 month |
|---|---|---|
| 2010-08-31 | $108.00K 10-Q · filed 2012-07-12 | |
| 2007-08-31 | $108.00K 10-Q · filed 2014-04-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |